If you have been reading about circadian rhythm and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2025-11-27. Where a claim depends on a specific study, the study is described rather than over-claimed.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.
Research interest in SR9009 grew from studies of circadian biology and metabolic disease. Preclinical reports describe effects on exercise capacity, muscle metabolism, and blood lipid levels in rodents, but these findings come from controlled laboratory settings. The compound has low oral bioavailability in animals, which limits systemic exposure after swallowing. Investigators often use injected routes in experiments to achieve measurable plasma concentrations. Human clinical data are sparse, no approved therapeutic product exists, and whether animal effects translate to humans remains an open question.
Regulatory and sporting contexts treat SR9009 as a prohibited substance in many elite competitions. Its presence on banned lists reflects concerns about performance enhancement and unknown long-term safety. Analytical chemists have developed methods to detect the parent compound and its metabolites in urine and blood. Literature discussions distinguish between in vitro potency, animal pharmacology, and anecdotal human reports. The latter are difficult to verify because products sold online may lack purity or contain different compounds.
Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.
Scientific discussion of SR9009 often separates animal evidence from human anecdote. Rodent studies provide controlled data on endurance, metabolism, and gene expression, but they use specific strains, doses, and treatment durations. Human reports are mostly uncontrolled and cannot establish cause and effect. Open questions include oral bioavailability, tissue distribution, metabolic stability, and long-term effects. Review articles generally call for more rigorous pharmacokinetic and safety research before any clinical use could be considered.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Binds REV-ERBα and REV-ERBβ in preclinical models |
| Molecular formula | C20H24ClN3O4S | Reported for the parent compound |
| CAS Registry Number | 1379686-30-2 | Common identifier in chemical databases |
| Appearance | Off-white to pale yellow solid | Typical research chemical solid |
| Solubility | Soluble in DMSO and ethanol; low in water | Class: small organic molecule |
SR9009 stability depends on temperature, moisture, light, and solvent. Solid material is generally kept cool and dry, while solutions may require protection from repeated warming and cooling. Degradation can appear as color changes, precipitate, or new chromatographic peaks. Researchers should follow supplier instructions and their own stability data. Long-term storage conditions for human use have not been established because the compound lacks approved clinical formulation.
SR9009 is supplied as a solid research chemical, often in milligram quantities. Laboratories typically weigh it in a controlled environment because fine powders can disperse. Stock solutions are commonly prepared in dimethyl sulfoxide and stored in small aliquots to reduce freeze-thaw cycles. Personal protective equipment and chemical fume hoods are standard when handling unknown or potent compounds. These practices address laboratory safety rather than human use.
Identity and purity of SR9009 samples are usually checked with chromatographic and spectrometric methods. High-performance liquid chromatography can separate the compound from related impurities, while mass spectrometry provides molecular mass confirmation. Nuclear magnetic resonance spectroscopy may be used for structural verification in research settings. No single method proves biological activity, and certificates of analysis should be reviewed alongside raw data. Independent testing is often needed because online products vary widely.
Gas chromatography-olfactometry (GC-O) is a technique that integrates the separation of volatile compounds using a gas chromatograph with the detection of odour using an olfactometer (human assessor). It was first invented and applied in 1964 by Fuller and co-workers. While GC separates volatile compounds from an extract, human olfaction detects the odour activity of each eluting compound. In this olfactometric detection, a human assessor may qualitatively determine whether a compound has odour activity or describe the odour perceived, or quantitatively evaluate the intensity of the odour or the duration of the odour activity. The olfactometric detection of compounds allows the assessment of the relationship between a quantified substance and the human perception of its odour, without instrumental detection limits present in other kinds of detectors. Compound identification still requires use of other detectors, such as mass spectrometry, with analytical standards.
=== Australia === The conservative Liberal–National Coalition issued a statement welcoming the news, with leader Sussan Ley remarking that "We should live in a world where dictators and despots face justice for their crimes." The Greens defense spokesman David Shoebridge condemned the operation as a breach of international law that "continues the world on a dangerous path of lawless aggression." Labor Against War, a political group within the ruling Labor Party, called on the government to condemn the strikes and to "immediately distance itself from the Trump administration, whose conduct is marked by [...] lawlessness at home and violent, reckless coercion abroad".
== Epidemiology == Calciphylaxis most commonly occurs in patients with end-stage renal disease who are on hemodialysis or who have recently received a kidney transplant. When reported in patients without end-stage renal disease (such as in earlier stages of chronic kidney disease or in normal kidney function), it is called non-uremic calciphylaxis by Nigwekar et al. Non-uremic calciphylaxis has been observed in patients with primary hyperparathyroidism, breast cancer (treated with chemotherapy), liver cirrhosis (due to hazardous alcohol use), cholangiocarcinoma, Crohn's disease, rheumatoid arthritis (RA), and systemic lupus erythematosus (SLE). Calciphylaxis, regardless of etiology, has been reported at an incidence of 35 in 10,000 dialysis patients per year in the United States, 4 in 10,000 patients in Germany, and less than 1 in 10,000 patients in Japan. It is unknown whether the higher incidence in the United States is due to genuinely higher incidence or due to underreporting in other countries. Annual incidence in kidney transplant patients and in non-uremic calciphylaxis patients is also unknown. The median age of patients at diagnosis of calciphylaxis is 60 years and the majority of these patients are women (60-70%). The location of lesions, central (located on the trunk) or peripheral (located on the extremities), is dependent on several risk factors. Central lesions are associated with younger patients, patients with a higher body mass index, and a higher risk of death than those who have peripheral-only lesions.
== Resin properties == The properties of the resin and fiber constituents influence the evolution of VBO (vacuum-bag-only) prepreg microstructures during cure. Generally, however, fiber properties and fiber bed architectures are standardized, whereas matrix properties drive both prepreg and process development. The dependence of microstructural evolution on resin properties, therefore, is critical to understand, and has been investigated by numerous authors. The presence of dry prepreg areas may suggest a need for low viscosity resins. However, Ridgard explains that VBO prepreg systems are designed to remain relatively viscous in the early stages of cure to impede infiltration and allow sufficient dry areas to persist for air evacuation to occur. Because the room temperature vacuum holds used to evacuate air from VBO systems are sometimes measured in hours or days, it is critical for the resin viscosity to inhibit cold flow, which could prematurely seal the air evacuation pathways. However, the overall viscosity profile must also permit sufficient flow at cure temperature to fully impregnate the prepreg, lest pervasive dry areas remain in the final part. Furthermore, Boyd and Maskell argue that to inhibit bubble formation and growth at low consolidation pressures, both the viscous and elastic characteristics of the prepreg must be tuned to the specific processing parameters encountered during cure, and ultimately ensure that a majority of the applied pressure is transferred to the resin.
Sources: en.wikipedia.org
=== Central laboratory data === Samples collected during a clinical trial may be sent to a single central laboratory for analysis. The clinical data manager liaises with the central laboratory and agrees data formats and transfer schedules in Data Transfer Agreement. The sample collection date and time may be reconciled against the CRF to ensure that all samples collected have been analysed.
Other powerful extensions to the dead-end elimination algorithm include the pairs elimination criterion, and the generalized dead-end elimination criterion. This algorithm has also been extended to handle continuous rotamers with provable guarantees. Although the Dead-end elimination algorithm runs in polynomial time on each iteration, it cannot guarantee convergence. If, after a certain number of iterations, the dead-end elimination algorithm does not prune any more rotamers, then either rotamers have to be merged or another search algorithm must be used to search the remaining search space. In such cases, the dead-end elimination acts as a pre-filtering algorithm to reduce the search space, while other algorithms, such as A*, Monte Carlo, Linear Programming, or FASTER are used to search the remaining search space.
=== Regulation of epithelial-mesenchymal transition and metastasis === ITGA1 mediates communication between collagen-rich ECM environments ands transforming growth factor-β (TGFβ) signaling pathways. In pancreatic cancer, ITGA1 promotes TGFβ/collagen-induced epithelial-mesenchymal transition (EMT), which is distinguishable by decreased epithelial markers such as E-cadherin (CDH1) as well as increased mesenchymal markers such as FN1, ZEB1, VIM, and MUC1. Through these mechanisms, ITGA1 promotes cellular plasticity. This is associated with invasion and metastatic progression. ITGA1 is required for efficient metastatic dissemination of living PDAC cells. Loss of ITGA1 reduces tumor spread in experimental models, displaying ITGA1's contribution to metastatic behavior by enabling tumor cells to respond to collagen and TGFβ-rich micro-environments.
The human vagina is an elastic, muscular canal that extends from the vulva to the cervix. The opening of the vagina lies in the urogenital triangle. The urogenital triangle is the front triangle of the perineum and also consists of the urethral opening and associated parts of the external genitalia. The vaginal canal travels upwards and backwards, between the urethra at the front, and the rectum at the back. Near the upper vagina, the cervix protrudes into the vagina on its front surface at approximately a 90 degree angle. The vaginal and urethral openings are protected by the labia. When not sexually aroused, the vagina is a collapsed tube, with the front and back walls placed together. The lateral walls, especially their middle area, are relatively more rigid. Because of this, the collapsed vagina has an H-shaped cross section. Behind, the upper vagina is separated from the rectum by the recto-uterine pouch, the middle vagina by loose connective tissue, and the lower vagina by the perineal body. Where the vaginal lumen surrounds the cervix of the uterus, it is divided into four continuous regions (vaginal fornices); these are the anterior, posterior, right lateral, and left lateral fornices. The posterior fornix is deeper than the anterior fornix. Supporting the vagina are its upper, middle, and lower third muscles and ligaments. The upper third are the levator ani muscles, and the transcervical, pubocervical, and sacrocervical ligaments. It is supported by the upper portions of the cardinal ligaments and the parametrium.
== Regulatory status == In 2023, China's National Health Commission officially approved peach gum as a "new food ingredient," establishing a recommended daily consumption limit of ≤30 grams per day. The regulatory approval noted insufficient safety data for infants, pregnant women, and nursing mothers, recommending these groups avoid consumption.
Sources: en.wikipedia.org
SR9009 is a synthetic small molecule studied as an agonist of the REV-ERB nuclear receptors. It is not an approved medicine, and its effects in humans are not well characterized.
No. It is a synthetic ligand that binds nuclear receptors, not a steroid or peptide hormone. Its activity depends on receptor binding rather than endocrine secretion.
Clinical evidence is limited. Most published data come from cell and animal experiments. Human safety and efficacy remain uncertain.
No. It is an investigational compound without approved therapeutic indications. It is sold for research purposes only in many jurisdictions.